Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Classification of clear c… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Classification of clear cell renal cell carcinoma based on PKM alternative splicing

Artikel i vetenskaplig tidskrift
Författare X. Y. Li
B. Turanli
K. Juszczak
W. Kim
M. Arif
Y. Sato
S. Ogawa
H. Turkez
J. Nielsen
Jan Borén
M. Uhlen
C. Zhang
A. Mardinoglu
Publicerad i Heliyon
Volym 6
Nummer/häfte 2
Sidor 10
ISSN 2405-8440
Publiceringsår 2020
Publicerad vid Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Sidor 10
Språk en
Länkar dx.doi.org/10.1016/j.heliyon.2020.e...
Ämnesord Bioinformatics, Cancer research, Systems biology, PKM, Alternative, splicing, Transcriptomics, Biomarker, Drug repositioning, pyruvate-kinase m2, isoform expression, cancer metabolism, bile-acids, signatures, migration, angiogenesis, progression, modulation, invasion, Science & Technology - Other Topics
Ämneskategorier Klinisk medicin

Sammanfattning

Clear cell renal cell carcinoma (ccRCC) accounts for 70-80% of kidney cancer diagnoses and displays high molecular and histologic heterogeneity. Hence, it is necessary to reveal the underlying molecular mechanisms involved in progression of ccRCC to better stratify the patients and design effective treatment strategies. Here, we analyzed the survival outcome of ccRCC patients as a consequence of the differential expression of four transcript isoforms of the pyruvate kinase muscle type (PKM). We first extracted a classification biomarker consisting of eight gene pairs whose within-sample relative expression orderings (REOs) could be used to robustly classify the patients into two groups with distinct molecular characteristics and survival outcomes. Next, we validated our findings in a validation cohort and an independent Japanese ccRCC cohort. We finally performed drug repositioning analysis based on transcriptomic expression profiles of drug-perturbed cancer cell lines and proposed that paracetamol, nizatidine, dimethadione and conessine can be repurposed to treat the patients in one of the subtype of ccRCC whereas chenodeoxycholic acid, fenoterol and hexylcaine can be repurposed to treat the patients in the other subtype.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?